ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1839

Elevated Plasma Cell-Free Mitochondrial DNA Defines a Subgroup of Lupus Patients with Membranous Lupus Nephritis

David Fernandez1, Maria A. Pabon2, Mikhail Olferiev1, Ana C. Hernandez2, Faryal Malick2, Leila Khalili1, Augustine M. K. Choi2, Kiichi Nakahira2 and Mary K. Crow1, 1Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Lupus, mitochondria and nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Systemic lupus erythematosus (SLE) is an autoimmune disease with protean manifestations, characterized by production of antibodies against nucleic acids and upregulation of type I interferon-inducible genes in a majority of SLE patients. The principal drivers of this interferon signature are still not well understood. Recent work has shown that oxidized mitochondrial DNA released by neutrophils can stimulate plasmacytoid dendritic cells to produce interferon-α. (1) We hypothesized that cell-free mitochondrial DNA might contribute to type I interferon production in SLE, and we sought to examine whether cell-free mtDNA levels were increased in SLE patients relative to controls, or during disease flares.

Methods: A retrospective analysis was performed using banked plasma samples from 164 patients in the FLARE SLE cohort along with 57 banked plasma samples from healthy donors. All patients in the FLARE cohort meet 4/11 ACR SLE classification criteria. DNA was isolated from the plasma samples and real-time quantitative PCR was performed, amplifying a target sequence in the mitochondrially-encoded gene NADH dehydrogenase I, as previously published. (2) In-depth clinical phenotyping of SLE patients in the cohort was performed and used to define subgroups of SLE patients, as well as the specific disease manifestations present during flares.

Results: No significant difference was seen in cell-free mtDNA in plasma from SLE patients versus healthy donors (HD – 3060.3 copies/uL, N=57, SLE – 3845.5 copies/uL, N=164, p=0.22). However, cell-free mtDNA levels were elevated in a subset of SLE patients with a history of membranous lupus nephritis, including those with a component of proliferative nephritis (WHO class V/III+V/IV+V), relative to patients with proliferative nephritis alone (WHO class III or class IV) (5313.9 copies/uL, N=34 vs. 2062.5 copies/uL, N=17, p=0.02). A subset of 70 patients had multiple samples collected at visits before, during, and after flares of disease activity. Cell-free mtDNA levels rose at the peak of disease activity as assessed by SLEDAI score in 11/16 flares of class V/III+V/IV+V nephritis (p=0.04), while it only did so in 4/11 of the remaining nephritis flares. In contrast, cell-free mtDNA rose at the peak of disease activity in only 4/20 flares where alopecia was present (p=0.02).

Conclusion: Cell-free mtDNA levels are elevated in a subset of SLE patients with a history of membranous nephritis, and were more likely to rise during flares of membranous nephritis versus other types of disease flares. References 1. Lood, C. et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat. Med. advance on, (2016). 2. Nakahira, K. et al. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Med. 10, e1001577; discussion e1001577 (2013).


Disclosure: D. Fernandez, None; M. A. Pabon, None; M. Olferiev, None; A. C. Hernandez, None; F. Malick, None; L. Khalili, None; A. M. K. Choi, None; K. Nakahira, None; M. K. Crow, Medimmune, 5.

To cite this abstract in AMA style:

Fernandez D, Pabon MA, Olferiev M, Hernandez AC, Malick F, Khalili L, Choi AMK, Nakahira K, Crow MK. Elevated Plasma Cell-Free Mitochondrial DNA Defines a Subgroup of Lupus Patients with Membranous Lupus Nephritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/elevated-plasma-cell-free-mitochondrial-dna-defines-a-subgroup-of-lupus-patients-with-membranous-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-plasma-cell-free-mitochondrial-dna-defines-a-subgroup-of-lupus-patients-with-membranous-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology